Carrington's DelSite Subsidiary Presents Data On Needle-Free Vaccine Technology

... Carrington Laboratories, Inc. (Nasdaq: CARN) reported today that GelVac(TM), a dry powder nasal delivery formulation for vaccines, showed both antigen stabilization and high immunogenic effect in preclinical models. In addition, ongoing studies of GelVac(TM) formulations incorporating influenza antigens exhibited the potential for long-term stability during storage at room temperature. [click link for full article] ...